A gold glyco-nanoparticle carrying a listeriolysin O peptide and formulated with Advax™ delta inulin adjuvant induces robust T-cell protection against listeria infection

Vaccine

Volumn 33, Issue 12, 2015, Pages 1465-1473

  Rodriguez Del Rio, Estela ^a   Marradi, Marco ^b,c   Calderon Gonzalez, Ricardo ^a   Frande Cabanes, Elisabet ^a   Penadés, Soledad ^b,c   Petrovsky, Nikolai ^d,e   Alvarez Dominguez, Carmen ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b CIC BIOMAGUNE   (Spain)

^c BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^d FLINDERS UNIVERSITY   (Australia)

^e VAXINE PTY LTD   (Australia)

Author keywords

Advax; Dendritic cells; Glyconanoparticles; Listeriosis; Vaccines

Indexed keywords

GAMMA INTERFERON; GOLD NANOPARTICLE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INULIN; LISTERIOLYSIN O; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; BACTERIAL TOXIN; BACTERIAL VACCINE; CYTOKINE; EPITOPE; GOLD; HEAT SHOCK PROTEIN; HEMOLYSIN; HLYA PROTEIN, LISTERIA MONOCYTOGENES; METAL NANOPARTICLE;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; LISTERIOSIS; MASS SPECTROMETRY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; CYTOLOGY; IMMUNOLOGY; LISTERIA MONOCYTOGENES; METABOLISM; SPLEEN; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL TOXINS; BACTERIAL VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; GOLD; HEAT-SHOCK PROTEINS; HEMOLYSIN PROTEINS; IMMUNITY, CELLULAR; INULIN; KILLER CELLS, NATURAL; LISTERIA MONOCYTOGENES; LISTERIOSIS; METAL NANOPARTICLES; MICE; MICE, INBRED BALB C; SPLEEN; T-LYMPHOCYTES; VACCINATION;

EID: 84924504401     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.062     Document Type: Article

References (40)

1. Brockstedt D.G., Bahjat K.S., Giedlin M.A., Liu W., Leong M., Luckett W., et al. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med 2005, 11(8):853-860.
2. Lauer P., Hanson B., Lemmens E.E., Liu W., Luckett W.S., Leong M.L., et al. Constitutive activation of the PrfA regulon enhances the potency of vaccines based on live-attenuated and killed but metabolically active Listeria monocytogenes strains. Infect Immun 2008, 76(8):3742-3753.
3. Starks H., Bruhn K.W., Shen H., Barry R.A., Dubensky T.W., Brockstedt D., et al. Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficiency. J Immunol 2004, 173:420-437.
4. at is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci USA 2013, 110:8668-8673.
5. Carrasco-Marin E., Rodriguez-Del Rio E., Frande-Cabanes E., Tobes R., Pareja E., Lecea-Cuello M.J., et al. Phagosomes induced by cytokines function as anti-Listeria vaccines: a novel role for functional compartmentalization of Stat-1 and cathepsin-D. J Biol Chem 2012, 287:14310-14324.
6. Kono M., Nakamura Y., Suda T., Uchijima M., Tsujimura K., Nagata T., et al. Enhancement of protective immunity against intracellular bacteria using type-1 polarized dendritic cell (DC) vaccine. Vaccine 2012, 30:2633-2639.
7. Mohamed W., Sethi S., Tchatalbachev S., Darji A., Chakraborty T. Protective immunity to Listeria monocytogenes infection mediated by recombinant Listeria innocua harboring the VGC locus. PLoS ONE 2012, 7(4):e35503.
8. Rodriguez-Del Rio E., Frande-Cabanes E., Tobes R., Pareja E., Lecea-Cuello M.J., Ruiz-Saez M., et al. The intact structural form of LLO in endosomes cannot protect against listeriosis. Int J Biochem Mol Biol 2011, 2(3):207-218.
9. Ansari M.A., Zubair S., Tufail S., Ahmad E., Khan M.R., Quadri Z., et al. Ether lipid vesicle-based antigens impart protection against experimental listeriosis. Int J Nanomed 2012, 7:2433-2447.
10. Vacas-Cordoba E., Pion M., Rasines B., Filippini D., Komber H., Ionov M., et al. Glycodendrimers as new tools in the search for effective anti-HIV DC-based immunotherapies. Nanomed: Nanotechnol, Biol Med 2013, 9(7):972-984.
11. Calderon-Gonzalez R., Frande-Cabanes E., Bronchalo-Vicente L., Lecea-Cuello M.J., Pareja E., Bosch-Martinez A., et al. Cellular vaccines in listeriosis: role of the Listeria antigen GAPDH. Front Cell Infect Microbiol 2014, 4(22):1-11. (eCollection 2014). 10.3389/fcimb.2014.00022.
12. Nagata T., Koide Y. Induction of specific CD8 T cells against intracellular bacteria by CD8 T cell-oriented immunization approaches. J Biomed Biotechnol 2010, 2010:764542.
13. Lee S.H., Carrero J.A., Uppaluri R., White J.M., Archambault J.M., Lai K.S., et al. Identifying the initiating events of anti-Listeria responses using mice with conditional loss of IFN-γ receptor subunit 1 (IFNGR1). J Immunol 2013, 191(8):4223-4234.
14. Pamer E.G. Immune responses to Listeria monocytogenes. Nat Rev Immunol 2004, 4:812-823.
15. Geginat G., Schenk S., Skoberne M., Goebel W., Hof H. A novel approach of direct ex vivo epitope mapping identifies dominant and subdominant CD4 and CD8T cell epitopes from Listeria monocytogenes. J Immunol 2001, 166:1877-1884.
16. Skoberne M., Geginat G. Efficient in vivo presentation of Listeria monocytogenes derived CD4 and CD8 cell epitopes in the absence of IFN-γ. J Immunol 2002, 168:1854-1860.
17. Angelakopoulos H., Loock K., Sisul D.M., Jensen E.R., Miller J.F., Hohmann E.L. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect Immun 2002, 70(7):3592-3601.
18. Pion M., Serramia M.J., Diaz L., Bryszewska M., Gallart T., Garcia F., et al. Phenotype and functional analysis of human monocytes-derived dendritic cells loaded with a carbosilane dendrimer. Biomaterials 2010, 31:8749-8758.
19. Lebel M.E., Daudelin J.F., Chartrand K., Tarrab E., Kaline U., Savard P., et al. Nanoparticle adjuvant sensing by TLR7 enhances CD8+ T cell-mediated protection from Listeria monocytogenes infection. J Immunol 2014, 192:1071-1078.
20. de la Fuente J.M., Barrientos A.G., Rojas T.C., Rojo J., Cañada J., Fernández A., et al. Gold glyconanoparticles as water-soluble polyvalent models to study carbohydrate interactions. Angew Chem Int Ed 2001, 40(12):2257-2261.
21. de la Fuente J.M., Penadés S. Glyconanoparticles: types, synthesis and applications in glycoscience, biomedicine and material science. Biochim Biophys Acta 2006, 1760:636-651.
22. Marradi M., Chiodo F., García I., Penadés S. Glyconanoparticles as multifunctional and multimodal carbohydrate systems. Chem Soc Rev 2013, 42:4728.
23. Safari D., Marradi M., Chiodo F., Th Dekker H.A., Shan Y., Adamo R., et al. Gold nanoparticles as carriers for a synthetic Streptococcus pneumoniae type 14 conjugate vaccine. Nanomedicine 2012, 7:651-662.
24. Chiodo F., Marradi M., Park J., Ram A.F., Penadés S., van Die I., et al. Galactofuranose-coated gold nanoparticles elicit a pro-inflammatory response in human monocyte-derived dendritic cells and are recognized by DC-SIGN. ACS Chem Biol 2014, 9(2):383-389.
25. Cooper P.D., Barclay T.G., Ginic-Markovic M., Petrovsky N. The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions. Glycobiology 2013, 23(10):1164-1174.
26. Honda-Okubo Y., Kolpe A., Li L., Petrovsky N. A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax™) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection. Vaccine 2014, 32(Aug (36)):4651-4659.
27. Larena M., Prow N.A., Hall R.A., Petrovsky N., Lobigs M. JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibody. J Virol 2013, 8:4395-4402.
28. Petrovsky N., Larena M., Siddharthan V., Prow N.A., Hall R.A., Lobigs M., et al. An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. J Virol 2013, 18:b10324-b10333.
29. Gordon D., Kelley P., Heinzel S., Cooper P., Petrovsky N. Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study. Vaccine 2014 Sep, (pii: S0264-410X(14)01293-6). 10.1016/j.vaccine.2014.09.034.
30. Cristillo A.D., Ferrari M.G., Hudacik L., Lewis B., Galmin L., Bowen B., et al. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol 2011, 92(Pt 1):128-140.
31. Gordon D.L., Sajkov D., Woodman R.J., Honda-Okubo Y., Cox M.J., Heinzel S., et al. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant. Vaccine 2012, 30:5047-5416.
32. Carrero J.A., Unanue E.R. Mechanisms and immunological effects of apoptosis caused by Listeria monocytogenes. Adv Immunol 2012, 113:157-174.
33. Lobgis M., Pavy M., Hall R.A., Lobgis P., Cooper P., Komiya T., et al. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol 2010, 91:1407-1417.
34. Layton R.C., Petrovsky N., Gigliotti A.P., Pollock Z., Knight J., Donart N., et al. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. Vaccine 2011, 29(37):6242-6251.
35. Honda-Okubo Y., Saade F., Petrovsky N. AdvaxTM, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine 2012, 30:5373-5381.
36. Martínez-Ávila O., Hijazi K., Marradi M., Clavel C., Campion C., Kelly C., et al. Gold manno-glyconanoparticles: multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN. Chem Eur J 2009, 15:9874-9888.
37. Ojeda R., De Paz J.L., Barrientos A.G., Martin-Lomas M., Penadés S. Preparation of multifunctional glyconanoparticles as a platform for potential carbohydrate-based anticancer vaccines. Carbohydr Res 2007, 342:448-459.
38. Uchiyama R., Yonehara S., Tsutsui H. Fas-mediated inflammatory response in Listeria monocytogenes infection. J Immunol 2013, 190(8):4245-4254.
39. Mitchell L.M., Brzoza-Lewis K.L., Henry C.J., Grayson J.M., Westcott M.M., Hitbold E.M. Distint responses of splenic dendritic cell subsets to infection with Listeria monocytogenes: maturation phenotype, level of infection, and T cell priming capacity ex vivo. Cell Immunol 2011, 268:79-86.
40. + dendrititc cells are an obligate cellular entry point for productive infection of Listeria monocytogenes. Immunity 2011, 35:236-248.